Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE: Ranibizumab with or without Targeted Panretinal Photocoagulation for Retinal Vein Occlusion
NCT01710839Phase 4Completed
- Sponsor
- Charles C. Wykoff
- Start
- Oct 2012
- Primary completion
- Oct 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in central retinal vein occlusion (CRVO), hemiretinal vein occlusion (HRVO), branch retinal vein occlusion (BRVO), sponsored by Charles C. Wykoff. Started Oct 2012; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)hemiretinal vein occlusion (HRVO)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01710839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710839.